Ex-Vivo Uterine Environment (EVE) Therapy Induced Limited Fetal Inflammation in a Premature Lamb Model

Introduction Ex-vivo uterine environment (EVE) therapy uses an artificial placenta to provide gas exchange and nutrient delivery to a fetus submerged in an amniotic fluid bath. Development of EVE may allow us to treat very premature neonates without mechanical ventilation. Meanwhile, elevations in fetal inflammation are associated with adverse neonatal outcomes. In the present study, we analysed fetal survival, inflammation and pulmonary maturation in preterm lambs maintained on EVE therapy using a parallelised umbilical circuit system with a low priming volume. Methods Ewes underwent surgical delivery at 115 days of gestation (term is 150 days), and fetuses were transferred to EVE therapy (EVE group; n = 5). Physiological parameters were continuously monitored; fetal blood samples were intermittently obtained to assess wellbeing and targeted to reference range values for 2 days. Age-matched animals (Control group; n = 6) were surgically delivered at 117 days of gestation. Fetal blood and tissue samples were analysed and compared between the two groups. Results Fetal survival time in the EVE group was 27.0 ± 15.5 (group mean ± SD) hours. Only one fetus completed the pre-determined study period with optimal physiological parameters, while the other 4 animals demonstrated physiological deterioration or death prior to the pre-determined study end point. Significant elevations (p<0.05) in: i) inflammatory proteins in fetal plasma; ii) selected cytokine/chemokine mRNA expression levels in fetal tissues; and iii) histological inflammatory score in fetal lung, were observed in the EVE group compared to the Control group. There was no significant difference (p>0.05) in surfactant protein mRNA expression level between the two groups. Conclusion In this study, we achieved limited fetal survival using EVE therapy. Despite this, EVE therapy only induced a modest fetal inflammatory response and did not promote lung maturation. These data provide additional insight into markers of treatment efficacy for the assessment of future studies.

[1]  A. Funakubo,et al.  Novel modification of an artificial placenta: pumpless arteriovenous extracorporeal life support in a premature lamb model , 2012, Pediatric Research.

[2]  J V Castell,et al.  Interleukin-6 and the acute phase response. , 1990, The Biochemical journal.

[3]  R. Schelonka,et al.  Plasma Concentrations of Inflammatory Cytokines Rise Rapidly during ECMO-related SIRS due to the Release of Pre-formed Stores in the Intestine , 2009, Laboratory Investigation.

[4]  Gerhard Ziemer,et al.  Effect of biopassive and bioactive surface-coatings on the hemocompatibility of membrane oxygenators. , 2007, Journal of biomedical materials research. Part B, Applied biomaterials.

[5]  A. Jobe,et al.  Intra-amniotic endotoxin increases pulmonary surfactant proteins and induces SP-B processing in fetal sheep. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[6]  V. Beneš,et al.  The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. , 2009, Clinical chemistry.

[7]  T. Taniguchi,et al.  Chorioamnionitis decreased incidence of respiratory distress syndrome by elevating fetal interleukin-6 serum concentration. , 2000, Human reproduction.

[8]  Eisuke Tatsumi,et al.  A novel small animal extracorporeal circulation model for studying pathophysiology of cardiopulmonary bypass , 2014, Journal of Artificial Organs.

[9]  L. Mann.  Effects in Sheep of Hypoxia on Levels of Lactate, Pyruvate, and Glucose in Blood of Mothers and Fetus , 1970, Pediatric Research.

[10]  M. Kaminski,et al.  Brain Injury in Very Preterm Children and Neurosensory and Cognitive Disabilities during Childhood: The EPIPAGE Cohort Study , 2013, PloS one.

[11]  P. Conn.  Animal models for the study of human disease , 2013 .

[12]  Toshio Hirano,et al.  Recombinant human interleukin‐6 (IL‐6/BSF‐2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes , 1988, FEBS letters.

[13]  T. Gourlay,et al.  The effect of circuit surface area on CD11b(mac-1) expression in a rat recirculation model. , 2001, Artificial organs.

[14]  J. Golej,et al.  Impact of Extracorporeal Membrane Oxygenation Modality on Cytokine Release During Rescue from Infant Hypoxia , 2003, Shock.

[15]  J. Gadzinowski,et al.  Neurological and developmental disabilities in ELBW and VLBW: follow-up at 2 years of age , 2011, Journal of Perinatology.

[16]  H. Wadenvik,et al.  Cytokine release during long-term extracorporeal circulation in an experimental model. , 1998, Artificial organs.

[17]  M. Kemp,et al.  Animal Models for the Study of Infection-Associated Preterm Birth , 2013 .

[18]  Joy E. Lawn,et al.  Born too soon: the global action report on preterm birth , 2012 .

[19]  J. Fortenberry,et al.  Neutrophil and cytokine activation with neonatal extracorporeal membrane oxygenation. , 1996, The Journal of pediatrics.

[20]  P. Sly,et al.  Endotoxin-induced lung maturation in preterm lambs is not mediated by cortisol. , 2000, American journal of respiratory and critical care medicine.

[21]  Eisuke Tatsumi,et al.  Investigation of the biological effects of artificial perfusion using rat extracorporeal circulation model , 2014, 2014 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[22]  Roberto Romero,et al.  The fetal inflammatory response syndrome. , 1998, American journal of obstetrics and gynecology.

[23]  P. Heinrich,et al.  Interleukin‐6 is the major regulator of acute phase protein synthesis in adult human hepatocytes , 1989, FEBS letters.

[24]  G. Nieman,et al.  Evidence of systemic cytokine release in patients undergoing cardiopulmonary bypass. , 2005, The journal of extra-corporeal technology.